Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology/Oncology Fellowship, Medicine, Duke University School of Medicine 2014 - 2017
  • Internal Medicine Residency, Indiana University, School of Medicine 2011 - 2014
  • D.O., University of New England 2011
• 

  Medical Licensure

  • 2017-01031. North Carolina. 2017
• 

  Previous Appointments & Affiliations

  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2019 - 2020
  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2017 - 2019
• Recognition
• 

  In the News

  • MAR 9, 2015

    The Washington Post

    Teaching doctors how to engage more and lecture less
• 

  Awards & Honors

  • Who’s Who Among Students in American Universities & Colleges. Who's Who Among Students. 2011
  • American Association for Cancer Research Scholar in Training Award. American Association for Cancer Research. 2005
• Expertise
• 

  Subject Headings

  • APOBEC
  • BRCA genes
  • Breast--Cancer--Immunotherapy
  • Cancer/testis Antigens
  • Homologous Recombination
  • Inflammatory Breast Cancer
  • Nanostring
  • Tumor Immune Microenvironment
  • Tumor Infiltrating Lymphocytes
  • X Chromosome Inactivation
  • X chromosome--Abnormalities
• 

  Global Scholarship

  • Research

    • United States of America (Country) 
• Research
• 

  Selected Grants

  • TBCRC 047: InCITe awarded by Gilead Sciences, Inc. 2023 - 2027
  • A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients with Early-Stage Triple Negative Breast Cancer (TNBC) awarded by G1 Therapeutics Inc. 2022 - 2027
  • A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) awarded by G1 Therapeutics Inc. 2022 - 2027
  • A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer awarded by Xilis, Inc. 2022 - 2027
  • TBCRC 047 awarded by Johns Hopkins University 2020 - 2025
  • GMI-1359-210 awarded by GlycoMimetics, Inc 2019 - 2024
  • Regional Oncolytic Poliovirus Immunotherapy for Breast Cancer awarded by Department of Defense 2016 - 2024
  • Beyond PD1: An immunotherapeutic strategy to stimulate and enable both T-cell and B-cell responses in immunosuppressive and non-mutated metastatic breast cancer awarded by Department of Defense 2020 - 2024
  • A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 (pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer awarded by Fox Chase Cancer Center 2018 - 2023
  • Phase II Study of Combination Ruxolitinib (INCB018424) with Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer protocol # TBCRC 039 awarded by Johns Hopkins University 2018 - 2023
  • Micro-Organospheres Drug Screen to Lead Care (MODEL) Platform to Guide Cancer Care awarded by Xilis, Inc. 2022 - 2023
  • A Phase II randomized study to evaluate the immunologic and antitumor activity of concurrent VRP-HER2 vaccination and Pembrolizumab for patients with advanced HER2-overexpressing breast cancer awarded by Merck Sharp & Dohme 2018 - 2023
  • Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2023
  • A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS awarded by Genentech, Inc. 2014 - 2022
  • Discovery and validation of putative oncogenic ROS1 alterations in metastatic breast cancer awarded by Metavivor 2020 - 2022
  • 3D Biology Signatures defined by Nanostring Max System awarded by North Carolina Biotechnology Center 2018 - 2019
• 

  External Relationships

  • Exact Sciences
  • G1 Therapeutics, Inc.
  • Guardant Health
  • Pfizer Inc.
  • Prime Education
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Parsons, Heather A., Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana G. Abramson, et al. “Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.” Medrxiv, March 8, 2023. https://doi.org/10.1101/2023.03.06.23286772.
       Full Text  Link to Item
    • Morse, Michael A., Erika J. Crosby, Jeremy Force, Takuya Osada, Amy C. Hobeika, Zachary C. Hartman, Peter Berglund, Jonathan Smith, and H Kim Lyerly. “Clinical trials of self-replicating RNA-based cancer vaccines.” Cancer Gene Ther, February 10, 2023, 1–9. https://doi.org/10.1038/s41417-023-00587-1.
       Full Text  Link to Item
    • Burnette, Sarah E., Emily Poehlein, Hui-Jie Lee, Jeremy Force, Kelly Westbrook, and Heather N. Moore. “Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer.” Breast Cancer Res Treat 197, no. 2 (January 2023): 369–76. https://doi.org/10.1007/s10549-022-06798-8.
       Full Text  Link to Item
    • Ademuyiwa, Foluso O., Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski, Mili Arora, et al. “A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013.” Npj Breast Cancer 8, no. 1 (December 30, 2022): 134. https://doi.org/10.1038/s41523-022-00500-3.
       Full Text  Link to Item
    • Plichta, Jennifer K., Samantha M. Thomas, Amanda R. Sergesketter, Rachel A. Greenup, Laura H. Rosenberger, Oluwadamilola M. Fayanju, Gretchen Kimmick, Jeremy Force, Terry Hyslop, and E Shelley Hwang. “A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates.” Ann Surg 275, no. 4 (April 1, 2022): 784–92. https://doi.org/10.1097/SLA.0000000000004231.
       Full Text  Link to Item
    • DiMarco, Ashley V., Xiaodi Qin, Brock J. McKinney, Nina Marie G. Garcia, Sarah C. Van Alsten, Elizabeth A. Mendes, Jeremy Force, et al. “APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.” Cancer Immunol Res 10, no. 1 (January 2022): 70–86. https://doi.org/10.1158/2326-6066.CIR-21-0146.
       Full Text  Link to Item
    • Tsao, Li-Chung, Jeremy Force, and Zachary C. Hartman. “Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.” Cancer Research 81, no. 18 (September 2021): 4641–51. https://doi.org/10.1158/0008-5472.can-21-1109.
       Full Text
    • Tamirisa, Nina P., Yi Ren, Brittany M. Campbell, Samantha M. Thomas, Oluwadamilola M. Fayanju, Jennifer K. Plichta, Laura H. Rosenberger, et al. “Treatment Patterns and Outcomes of Women with Breast Cancer and Supraclavicular Nodal Metastases.” Ann Surg Oncol 28, no. 4 (April 2021): 2146–54. https://doi.org/10.1245/s10434-020-09024-1.
       Full Text  Link to Item
    • Isaacs, James, Carey Anders, Heather McArthur, and Jeremy Force. “Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.” Curr Treat Options Oncol 22, no. 5 (March 20, 2021): 38. https://doi.org/10.1007/s11864-021-00833-4.
       Full Text  Link to Item
    • Plichta, Jennifer K., Yi Ren, Caitlin E. Marks, Samantha M. Thomas, Rachel A. Greenup, Laura H. Rosenberger, Oluwadamilola M. Fayanju, Susan G. R. McDuff, E Shelley Hwang, and Jeremy Force. “Surgery for Men with Breast Cancer: Do the Same Data Still Apply?” Ann Surg Oncol 27, no. 12 (November 2020): 4720–29. https://doi.org/10.1245/s10434-020-08901-z.
       Full Text  Link to Item
    • Crosby, Erika J., Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, et al. “Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.” Clin Cancer Res 26, no. 17 (September 1, 2020): 4670–81. https://doi.org/10.1158/1078-0432.CCR-20-0389.
       Full Text  Link to Item
    • Lin, Chao-Chieh, Nathaniel W. Mabe, Yi-Tzu Lin, Wen-Hsuan Yang, Xiaohu Tang, Lisa Hong, Tianai Sun, et al. “RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence.” Cell Death Differ 27, no. 7 (July 2020): 2234–47. https://doi.org/10.1038/s41418-020-0499-y.
       Full Text  Link to Item
    • Fayanju, Oluwadamilola M., Yi Ren, Gita Suneja, Samantha M. Thomas, Rachel A. Greenup, Jennifer K. Plichta, Laura H. Rosenberger, Jeremy Force, Terry Hyslop, and E Shelley Hwang. “Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis.” Int J Radiat Oncol Biol Phys 106, no. 2 (February 1, 2020): 377–89. https://doi.org/10.1016/j.ijrobp.2019.10.039.
       Full Text  Open Access Copy  Link to Item
    • Fayanju, Oluwadamilola M., Yi Ren, Rachel A. Greenup, Jennifer K. Plichta, Laura H. Rosenberger, Jeremy Force, Gita Suneja, et al. “Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.” Breast Cancer Res Treat 180, no. 1 (February 2020): 207–17. https://doi.org/10.1007/s10549-020-05529-1.
       Full Text  Link to Item
    • Force, Jeremy, Jorge Henrique Santos Leal, and Heather L. McArthur. “Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.” Curr Treat Options Oncol 20, no. 4 (March 28, 2019): 35. https://doi.org/10.1007/s11864-019-0634-5.
       Full Text  Link to Item
    • Shariff, Afreen Idris, Sohail Syed, Rebecca A. Shelby, Jeremy Force, Jeffrey Melson Clarke, David D’Alessio, and Leonor Corsino. “Novel cancer therapies and their association with diabetes.” J Mol Endocrinol 62, no. 2 (February 1, 2019): R187–99. https://doi.org/10.1530/JME-18-0002.
       Full Text  Link to Item
    • Devi, Gayathri R., Holly Hough, Nadine Barrett, Massimo Cristofanilli, Beth Overmoyer, Neil Spector, Naoto T. Ueno, et al. “Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium.” J Cancer 10, no. 15 (2019): 3344–51. https://doi.org/10.7150/jca.31176.
       Full Text  Open Access Copy  Link to Item
    • Fayanju, Oluwadamilola M., Yi Ren, Samantha M. Thomas, Rachel A. Greenup, Jennifer K. Plichta, Laura H. Rosenberger, Nina Tamirisa, et al. “The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).” Ann Surg 268, no. 4 (October 2018): 591–601. https://doi.org/10.1097/SLA.0000000000002953.
       Full Text  Link to Item
    • Force, Jeremy, Lynn J. Howie, Sara E. Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, et al. “Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.” Clin Breast Cancer 18, no. 5 (October 2018): 410–17. https://doi.org/10.1016/j.clbc.2018.02.010.
       Full Text  Link to Item
    • Ong, Cecilia T., Brittany M. Campbell, Samantha M. Thomas, Rachel A. Greenup, Jennifer K. Plichta, Laura H. Rosenberger, Jeremy Force, et al. “Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database.” Ann Surg Oncol 25, no. 8 (August 2018): 2249–60. https://doi.org/10.1245/s10434-018-6533-3.
       Full Text  Link to Item
    • Force, Jeremy, and April Ks Salama. “First-line treatment of metastatic melanoma: role of nivolumab.” Immunotargets Ther 6 (2017): 1–10. https://doi.org/10.2147/ITT.S110479.
       Full Text  Open Access Copy  Link to Item
    • Spiegel, D., P. K. Marcom, B. Peterson, J. Force, L. Howie, M. Palta, R. C. Blitzblau, and J. K. Horton. “Acute Toxicity in Patients With HER2-Positive Breast Cancer Treated With Adjuvant Radiation Therapy and Concurrent Trastuzumab and Pertuzumab.” Int J Radiat Oncol Biol Phys 96, no. 2S (October 1, 2016): E9–10. https://doi.org/10.1016/j.ijrobp.2016.06.619.
       Full Text  Link to Item
    • Force, Jeremy, Romil Saxena, Bryan P. Schneider, Anna M. Storniolo, George W. Sledge, Naga Chalasani, and Raj Vuppalanchi. “Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine.” J Clin Oncol 34, no. 3 (January 20, 2016): e9-12. https://doi.org/10.1200/JCO.2013.49.8543.
       Full Text  Link to Item
    • Force, Jeremy, Arun Rajan, Eva Dombi, Seth M. Steinberg, and Giuseppe Giaccone. “Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.” J Thorac Oncol 6, no. 7 (July 2011): 1267–73. https://doi.org/10.1097/JTO.0b013e3182199be2.
       Full Text  Link to Item
    • Kelly, Ronan J., Arun Rajan, Jeremy Force, Ariel Lopez-Chavez, Corrine Keen, Liang Cao, Yunkai Yu, et al. “Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.” Clin Cancer Res 17, no. 5 (March 1, 2011): 1190–99. https://doi.org/10.1158/1078-0432.CCR-10-2331.
       Full Text  Link to Item
    • Girnun, Geoffrey D., Liang Chen, Jessica Silvaggi, Ronny Drapkin, Lucian R. Chirieac, Robert F. Padera, Rabi Upadhyay, et al. “Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.” Clin Cancer Res 14, no. 20 (October 15, 2008): 6478–86. https://doi.org/10.1158/1078-0432.CCR-08-1128.
       Full Text  Link to Item
    • Norden-Zfoni, Anat, Jayesh Desai, Judith Manola, Paul Beaudry, Jeremy Force, Robert Maki, Judah Folkman, et al. “Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.” Clin Cancer Res 13, no. 9 (May 1, 2007): 2643–50. https://doi.org/10.1158/1078-0432.CCR-06-0919.
       Full Text  Link to Item
    • Celik, Ilhan, Oguzkan Sürücü, Carsten Dietz, John V. Heymach, Jeremy Force, Iris Höschele, Christian M. Becker, Judah Folkman, and Oliver Kisker. “Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve.” Cancer Res 65, no. 23 (December 1, 2005): 11044–50. https://doi.org/10.1158/0008-5472.CAN-05-2617.
       Full Text  Link to Item
    • Beaudry, Paul, Jeremy Force, George N. Naumov, Andrew Wang, Cheryl H. Baker, Anderson Ryan, Shay Soker, Bruce E. Johnson, Judah Folkman, and John V. Heymach. “Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.” Clin Cancer Res 11, no. 9 (May 1, 2005): 3514–22. https://doi.org/10.1158/1078-0432.CCR-04-2271.
       Full Text  Link to Item
    • Schuch, Gunter, John V. Heymach, Masashi Nomi, Marcelle Machluf, Jeremy Force, Anthony Atala, Joseph P. Eder, Judah Folkman, and Shay Soker. “Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells.” Cancer Res 63, no. 23 (December 1, 2003): 8345–50.
       Link to Item

  • Conference Papers

    • Kimmick, Gretchen, Smrithi Davakaran, Heather Moore, Cynthia Rose, Pamela Gentry, Michael Willis, Susan Dent, et al. “Abstract P4-10-06: Best quality care from a distance (BQual-D): Maintaining high quality care for hormone receptor positive (HR+) metastatic breast cancer (MBC) during the COVID pandemic, description of the program and provider satisfaction.” In Cancer Research, Vol. 82. American Association for Cancer Research (AACR), 2022. https://doi.org/10.1158/1538-7445.sabcs21-p4-10-06.
       Full Text
    • Sammons, Sarah, Andrew Elliott, Jeremy Force, Saranya Chumsri, Carey Anders, Antoinette R. Tan, Daniel Magee, et al. “Abstract P2-08-08: Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.” In Cancer Research, Vol. 82. American Association for Cancer Research (AACR), 2022. https://doi.org/10.1158/1538-7445.sabcs21-p2-08-08.
       Full Text
    • Yen, Jennifer, Leylah Drusbosky, Caroline Weipert, Nicole Zhang, David Hanna, Catalin Barbacioru, Hao Wang, et al. “Abstract P5-13-29: Analytical and clinical validation of a ctDNA assay for detecting copy number loss and structural rearrangement variants contributing to homologous recombination and repair (HRR) deficiency.” In Cancer Research, Vol. 82. American Association for Cancer Research (AACR), 2022. https://doi.org/10.1158/1538-7445.sabcs21-p5-13-29.
       Full Text
    • Berdunov, V., Cuyun G. Carter, E. Laws, R. Luo, C. Russell, S. Campbell, J. Force, and Y. G. Abdou. “COST-EFFECTIVENESS ANALYSIS OF THE ONCOTYPE DX BREAST RECURRENCE SCORE (R) TEST FOR HR+/HER2-EARLY-STAGE BREAST CANCER IN THE US.” In Value in Health, 25:S352–53, 2022.
       Link to Item
    • Burnette, S., E. Poehlein, H. -. J. Lee, J. Force, K. Westbrook, and H. Moore. “253P Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) + fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC).” In Annals of Oncology, 32:S470–S470. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.536.
       Full Text
    • Drusbosky, Leylah, Mehmet Asim Bilen, Georges Azzi, Pedro C. Barata, Patrick M. Boland, Alan Haruo Bryce, Young Kwang Chae, et al. “Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.” In Journal of Clinical Oncology, 39:3040–3040. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.3040.
       Full Text
    • Sammons, Sarah, Andrew Elliott, Jeremy Meyer Force, Nicholas C. DeVito, Paul Kelly Marcom, Sandra M. Swain, Antoinette R. Tan, et al. “Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.” In Journal of Clinical Oncology, 39:1091–1091. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.1091.
       Full Text
    • Taylor, Mary Love, Hiba I. Dada, Hannah Florian, Paul Kelly Marcom, Carey K. Anders, Leylah Drusbosky, and Jeremy Meyer Force. “Identification of pathogenic CDK12 alterations in cell-free DNA (cfDNA) from patients with breast cancer.” In Journal of Clinical Oncology, 39:1028–1028. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.1028.
       Full Text
    • Ademuyiwa, Foluso O., Feng Gao, Ina Chen, Donald W. Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, et al. “Nci 10013-A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel, with or without atezolizumab in triple negative breast cancer (TNBC).” In Cancer Research, Vol. 81, 2021.
       Link to Item
    • Moore, Heather, Scott Shofer, Amy Guisinger, Gloria Broadwater, Jeremy Force, Sarah Sammons, Carey Anders, and Kelly Westbrook. “Feasibility of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with fam-trastuzumab deruxtecan.” In Cancer Research, Vol. 81, 2021.
       Link to Item
    • Taylor, Mary Love, Benjamin Mayro, Leylah Drusbosky, Carey Anders, and Jeremy Force. “Identification of pathogenic RET alterations in cell-free DNA (cfDNA) from patients with metastatic breast cancer.” In Cancer Research, Vol. 81, 2021.
       Link to Item
    • Taylor, Mary Love, Benjamin Mayro, Leylah Drusbosky, Robin Batchelder, P Kelly Marcom, Carey Anders, and Jeremy Force. “Identification of pathogenic FGFR1, FGFR2, and FGFR3 alterations in cell-free DNA (cfDNA) from patients with metastatic breast cancer.” In Cancer Research, Vol. 81, 2021.
       Link to Item
    • Force, Jeremy, Ethan S. Sokol, Mary Love Taylor, Dale Huang, Paul K. Marcom, Monika Davare, and Jeffrey Marks. “Abstract P3-06-09: Incidence of ROS1 genomic alterations in breast cancer.” In Cancer Research, Vol. 80. American Association for Cancer Research (AACR), 2020. https://doi.org/10.1158/1538-7445.sabcs19-p3-06-09.
       Full Text
    • Force, Jeremy, Xiaodi Qin, Dadong Zhang, P Kelly Marcom, Jeffrey Marks, Mary Love Taylor, Carey Anders, Kouros Owzar, and Jichun Xie. “Abstract P1-06-02: Characterization of gene- and sample-level APOBEC mutagenesis enrichment with respect to intrinsic subtypes, tumor mutational burden, and immune composition in breast cancer.” In Cancer Research, Vol. 80. American Association for Cancer Research (AACR), 2020. https://doi.org/10.1158/1538-7445.sabcs19-p1-06-02.
       Full Text
    • Sammons, Sarah, Yi Ren, Jeremy Force, Oluwadamilola M. Fayanju, Laura H. Rosenberger, Jennifer K. Plichta, Gretchen Kimmick, et al. “Abstract P3-08-10: Characterization of oncotype DX recurrence score and chemotherapy utilization patterns in young women (≤40) with early stage ER+/HER-, lymph node negative breast cancer.” In Cancer Research, Vol. 80. American Association for Cancer Research (AACR), 2020. https://doi.org/10.1158/1538-7445.sabcs19-p3-08-10.
       Full Text
    • Force, Jeremy Meyer, Mary Love Taylor, Leylah Drusbosky, Jennifer Yen, Paul Kelly Marcom, Carey K. Anders, and Jeffrey R. Marks. “Identification of pathogenic ROSI alterations in cell-free DNA (cfDNA) from patients with breast cancer.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • LoRusso, Patricia, Mary Josephine Paula Pilat, Cesar Augusto Santa-Maria, Roisin M. Connolly, Erin Elizabeth Roesch, Anosheh Afghahi, Hyo S. Han, et al. “Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Plichta, Jennifer, Yi Ren, Caitlin Marks, Samantha Thomas, Rachel Greenup, Laura Rosenberger, Oluwadamilola Fayanju, Shelley Hwang, and Jeremy Force. “Surgery for Men with Breast Cancer: Do the Same Data Still Apply?” In Annals of Surgical Oncology, 27:S394–95, 2020.
       Link to Item
    • Brauer, H., Y. Ren, L. Yang, J. Force, D. Henderson, and S. Ferree. “Genomic Characterization of Breast Cancer Heterogeneity Using Breast Cancer 360.” In Journal of Molecular Diagnostics, 21:1225–1225. ELSEVIER SCIENCE INC, 2019.
       Link to Item
    • Force, J., J. Plichta, I. Stashko, G. Kimmick, K. Westbrook, S. Sammons, S. Hwang, et al. “Abstract P3-08-07: Distinct biological signatures describe differences in BRCA mutated subgroups.” In Cancer Research, Vol. 79. American Association for Cancer Research (AACR), 2019. https://doi.org/10.1158/1538-7445.sabcs18-p3-08-07.
       Full Text
    • Sammons, S., C. Yip, G. Anderson, J. Force, K. Marcom, K. Westbrook, C. K. Anders, K. Blackwell, and K. Wood. “Abstract P1-06-04: Small-molecule screening nominates diverse combination therapies that sensitize BRCA mutant and wild-type triple negative breast cancer to PARP inhibition.” In Cancer Research, Vol. 79. American Association for Cancer Research (AACR), 2019. https://doi.org/10.1158/1538-7445.sabcs18-p1-06-04.
       Full Text
    • Landa, Karenia, Eda Holl, Michael Brown, James Herndon, Lars Grimm, Jeremy Force, Darell Bigner, Shelley Hwang, Matthias Gromeier, and Smita Nair. “Abstract LB-302: Oncolytic poliovirus-mediated inflammation and immunity in breast cancer.” In Cancer Research, Vol. 78. American Association for Cancer Research (AACR), 2018. https://doi.org/10.1158/1538-7445.am2018-lb-302.
       Full Text
    • Force, Jeremy Meyer, Sarah Abbott, Gloria Broadwater, Ilona Stashko, Kelly E. Westbrook, Gretchen Genevieve Kimmick, Sarah LeNoir Sammons, et al. “Immune profiling of BRCA-mutated breast cancers.” In Journal of Clinical Oncology, 36:585–585. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.585.
       Full Text
    • Force, Jeremy, Eda Holl, Michael Brown, Paul Kelly Marcom, Lars Grimm, David Boczkowski, Victoria Frazier, et al. “Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.” In Journal of Clinical Oncology, 36:e12641–e12641. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e12641.
       Full Text
    • Thomas, S. M., O. M. Fayanju, J. K. Plichta, L. H. Rosenberger, J. Force, T. Hyslop, E. S. Hwang, and R. A. Greenup. “Treatment Patterns and Outcomes for Breast Cancer with Isolated Supraclavicular Metastases.” In Annals of Surgical Oncology, 25:S26–S26. SPRINGER, 2018.
       Link to Item
    • Campbell, Brittany Morgan, Samantha Marie Thomas, Cecilia Tuongquang Ong, Rachel Adams Greenup, Jennifer Kay Plichta, Laura Horst Rosenberger, Jeremy Meyer Force, Terry Hyslop, Eun-Sil Shelley Hwang, and Oluwadamilola Motunrayo Fayanju. “The epidemiology of metaplastic breast cancer: A review of 2,500 cases from the national cancer database.” In Journal of Clinical Oncology, 35:1570–1570. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.1570.
       Full Text
    • Ong, Cecilia Tuongquang, Samantha Marie Thomas, Brittany Morgan Campbell, Rachel Adams Greenup, Jennifer Kay Plichta, Laura Horst Rosenberger, Jeremy Meyer Force, Terry Hyslop, Eun-Sil Shelley Hwang, and Oluwadamilola Motunrayo Fayanju. “A population-based analysis of treatment and outcomes in 2,500 metaplastic breast cancer patients.” In Journal of Clinical Oncology, 35:532–532. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.532.
       Full Text
    • Force, J., S. Abbott, G. Broadwater, G. Kimmick, K. Westbrook, S. Hwang, N. Kauff, et al. “Abstract P2-04-19: Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients.” In Cancer Research, Vol. 77. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/1538-7445.sabcs16-p2-04-19.
       Full Text
    • Force, Jeremy Meyer, Lynn Jackson Howie, Sara Abbott, Rex C. Bentley, Paul K. Marcom, Gretchen Genevieve Kimmick, Kelly E. Westbrook, et al. “Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens.” In Journal of Clinical Oncology, 34:602–602. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.602.
       Full Text
    • Howie, L. J., P. K. Marcom, D. L. Topping, J. Force, R. Emerson, N. A. Bhavsar, S. E. Abbott, M. Parks, H. S. Robins, and K. L. Blackwell. “Abstract P4-14-16: T-cell clonality increases after neoadjuvant treatment with trastuzumab and pertuzumab.” In Cancer Research, Vol. 76. American Association for Cancer Research (AACR), 2016. https://doi.org/10.1158/1538-7445.sabcs15-p4-14-16.
       Full Text
    • Force, J., A. Rajan, E. Dombi, S. M. Steinberg, and G. Giaccone. “Volumetric analysis of advanced thymic malignancies.” In Journal of Clinical Oncology, 28:7096–7096. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.7096.
       Full Text
    • Kelly, R. J., J. Force, A. Rajan, C. Keen, B. Turkbey, L. Cao, M. Raffeld, S. M. Steinberg, J. J. Wright, and G. Giaccone. “Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S).” In Journal of Clinical Oncology, 28:7626–7626. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.7626.
       Full Text
    • Force, J. M., A. Briggs, K. Lowe, E. Lifshits, J. Foklman, and J. V. Heymach. “The Differential Regulation of Taxane Sensitivity by Hypoxia in Endothelial and Lung Carcinoma Cells,” n.d.
    • Force, J. M., J. V. Heymach, B. Beaudry, A. C. Wang, C. Baker, A. Ryan, J. Folkman, and S. Soker. “Effects of the VEGFR-2 Tyrosine Kinase Inhibitor ZD6474 and Docetaxel on Circulating Endothelial Cells (CEC): Implications for Use as a Surrogate Marker,” n.d.
    • Force, J. M., J. V. Heymach, B. Beaudry, A. Norden-Zfoni, D. Prox, A. Briggs, G. Naumov, et al. “Circulating Endothelial Cells as a Marker of Antiangiogenic Activity,” n.d.
    • Force, J. M., J. V. Heymach, M. H. Kulke, C. S. Fuchs, S. Connors, C. Sidor, D. George, J. P. Eder, J. Folkman, and S. Soker. “Circulating Endothelial Cells as a Surrogate Marker of Antiangiogenic Activity in Patients Treated with Endostatin,” n.d.
• Scholarly, Clinical, & Service Activities
• 

  Service to the Profession

  • President. UNECOM New England Research Club . University of New England College of Osteopathic Medicine. 2007 - 2008  2007 - 2008
  • UNECOM AMSA Regional Representative and Chair of Medical Education. University of New England American Medical Student Association (AMSA). 2006 - 2008  2006 - 2008
• 

  Clinical Activities

  • Research Experience:

    Hematology/Oncology Fellow: Primary Mentors – Dr. P. Kelly Marcom, Dr. Kent Weinhold, Dr. Smita Nair, & Dr. Neil Spector. Duke University Medical Center, Department of Hematology/Oncology, Durham, NC.  July 2014-Present.

    • Development of investigator-initiated clinical trials studying novel immunotherapeutic strategies in breast cancer
      • Development and IRB approval of a clinical trial investigating early stage triple negative breast cancer immune infiltrate changes from pembrolizumab
    • Investigating relationships between the immune system, tumor microenvironment, and hereditary breast cancers
    • Identified an immunosuppressive phenotype in early stage HER2+ breast cancer patients treated with THCP not achieving a pathologic complete response
      • Helped to elucidate T-cell receptor deep sequencing changes in early stage HER2+ breast cancer patients treated with TCHP
    • Investigate relationships between APOBEC3B mutations in breast cancers
    • Assist in initiating the Duke Inflammatory Breast Cancer Clinic

     

    Medical Research Scholars Program (HHMI/CRTP): Clinical Mentor - Dr. Giuseppe Giaccone, National Institutes of Health, Bethesda, MD.  August 2009-July 2010.

    • Partook in elucidating the benefits CT based volumetric measurements could aid in clinical decision making against RECIST criteria in thymic malignancies treated with belinostat.
    • Participated in the clinical research design and writing of protocols entitled Molecular Profiling of NSCLC, SCLC, and Thymic Malignancies With the Intention to Treat. 
    • Contributed towards the data analysis of ancillary studies in a phase II clinical trial of metastatic NSCLC patients treated with Sorafenib as a single agent.
    • Invited to present oral presentations at annual FYI-CCR NIH Colloquium March 2010 and Annual CRTP Colloquium May 2010.
    • Presented and contributed to weekly CRTP journal club discussions.
    • Took part in weekly lecture series discussions held by Nobel laureates and other leaders in various medical fields.
    • Obtained advanced education involving The Biology of Cancer and Principles of Clinical Pharmacology sponsored by the Foundation for Advanced Education in the Sciences at the National Institutes of Health.

     

    Summer Research Medical Student: Research Mentor - Dr. Kwok Wong, Dana Farber Cancer Institute, Boston, MA.  May 2007-August 2007.

    • Utilized and applied scientific techniques such as DNA isolation, PCR, cloning, and tissue culture to aid in the creation of transgenic murine models of cancer.
    • Treated transgenic mouse models of cancer with molecular targeted therapies and learned and performed MRI examinations on these mice to demonstrate decreased tumor burden. 

     

    Research Technician: Research Mentor: Dr. Judah Folkman, Children’s Hospital Boston, MA.  July 2002-October 2005.

    • Planned and performed extensive laboratory techniques involving murine models of cancer, surgical procedures, flow cytometry, tissue/cell culturing, PCR, gel electrophoresis, and other assays to measure angiogenesis.
    • Developed methodologies for measuring circulating endothelial cell surrogate markers using flow cytometry. (Faculty advisor: Dr. John Heymach)
    • Measured circulating endothelial cells in blood drawn from cancer patients being treated with angiogenesis inhibitors in clinical trials performed at the Dana-Farber Cancer Institute.  The goal of this work was to investigate surrogate markers of angiogenesis in cancer patients.
    • Performed Master’s laboratory thesis on the combinations of taxanes and anti-angiogenic agents: conventional vs. metronomic dosing.

     

     

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.